NRXP - NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc.
1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
(484) 254-6134
https://www.nrxpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Stephen H. Willard Esq. | CEO & Director | 501.19k | N/A | 1961 |
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer & Director | 926.01k | N/A | 1957 |
| Dr. Seth L. Van Voorhees Ph.D. | CFO & Treasurer | 399.96k | N/A | 1961 |
| Mr. Riccardo Panicucci Ph.D. | Chief Technology Officer | 220k | N/A | 1962 |
| Suzanne Messere | Investor Relations | N/A | N/A | N/A |
| Dr. Michael Kunz | Gen. Counsel & Corp. Sec. | N/A | N/A | 1965 |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist | N/A | N/A | 1947 |
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer & Sr. Scientist | N/A | N/A | N/A |
| Mr. Matthew Patrick Duffy | Chief Bus. Officer | N/A | N/A | 1963 |
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Corporate governance
NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
